RE: More data than expected10 Apr 2024 08:50
Overall, most compelling was the fact that no maximum tolerated dose was achieved.
The poster also includes an overview of the best overall response, stratified by FAP status. In the 15 patients with cancer types categorised as high FAP
(based on a literature review), there were: 2 partial responses (≥30% decrease in the sum of diameters of the target lesion) of which 1 is confirmed
and 1 is unconfirmed and both are ongoing; and 3 minor responses (a 10-29% decrease), with two ongoing. Ongoing patients could potentially see
improved responses in the future. Seven patients had stable disease for ≥16 weeks. Recall that patients in this trial had been heavily pretreated (median of three prior regimens) and most patients would typically not be offered an anthracycline like doxorubicin. Hence RESPONSES WERE NOT EXPECTED”
Massive
Next results end April